Back to search results

Robotic Surgery and Heated Chemotherapy for Gastric Cancer with Peritoneal Metastasis

This study is testing a new way to treat gastric (stomach) cancer that has spread to the lining of the abdomen (peritoneum). It combines robotic surgery (gastrectomy) with heated chemotherapy (Cisplatin) given directly into the abdomen (HIPEC). The goal is to see if this approach, which uses smaller incisions than traditional surgery, can lead to fewer complications and shorter hospital stays. Researchers will be looking at how long people stay in the hospital, how often they need to be readmitted within 30 days, and any side effects. You might be able to join if you are 18-80 years old, have gastric or gastroesophageal junction adenocarcinoma, and meet certain health requirements. This study plans to enroll 40 participants, and its current status is unclear.

Study design
This is a Phase II interventional study, meaning all 40 participants will receive the study treatment. It is designed to evaluate the safety and effectiveness of the intervention.
What's involved
You would undergo a robotic gastrectomy and receive Cisplatin via HIPEC. You would also have imaging tests like CT scans, PET/CT scans, or MRIs.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track your hospital stay, readmission rates, and adverse events for up to 30 days after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05753306

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Recruiting
PHASE2Ages 18–80InterventionalTreatment
Mayo Clinic
~40 participants
Updated 2026-04-08 on ClinicalTrials.gov
What's tested:CisplatinComputed TomographyGastrectomyMagnetic Resonance ImagingPositron Emission TomographyQuestionnaire Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hospital length of stay
Measured over Up to 30 days post-surgery
+2 more outcomes measured

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Metastatic Malignant Neoplasm in the Peritoneum

Explore related trials

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

NCT05753306

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Travis E Grotz, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Restricted to 18 to 80 years of age
Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
Histologic confirmation of gastric adenocarcinoma including all subtypes and Siewert type II/III gastroesophageal (GE) junction adenocarcinomas
Absolute neutrophil count \>= 1,500 / uL
Platelets \>= 50,000 / Ul
Serum creatinine \<= 1.5 mg / dL
Adequate nutritional status (Albumin \>= 3.5)
Metastasis confined to the peritoneum:
Positive peritoneal cytology
Peritoneal metastasis on diagnostic laparoscopy
Peritoneal metastasis on imaging
Response to systemic chemotherapy defined as at least one of the following:
Reduction (\>= 30%) in standardized uptake value (SUV) max \[Response Evaluation Criteria in Solid Tumors (RECIST) criteria\]
Reduction in size of primary tumor, regional lymph node or peritoneal metastasis on imaging (\>= 20% decrease in the longest diameter of target lesion) RECIST criteria
Reduction ( \>= 30%) in Peritoneal Carcinomatosis Index (PCI) or conversion of peritoneal cytology
Reduction ( \>= 30%) in serum tumor markers CEA or CA 19-9
Peritoneal Carcinomatosis Index (PCI) =\< 7 and surgeon deems high likelihood for a complete cytoreduction
Body Mass Index (BMI) =\< 35 kg/m\^2

Exclusion

Distant metastatic disease not limited to peritoneum, such as solid organ metastases (liver, lung, bone, distant lymph node, etc)
Malignant ascites at time of study enrollment
Comorbidities that would preclude protocol therapy
Subjects deemed unable to comply with study and/or follow-up procedures
Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity

What this trial measures

  • Hospital length of stayUp to 30 days post-surgery

    Recorded as number of days in hospital following surgery.

  • 30 day readmission rateUp to 30 days post-surgery

    Assessed by the number of participants who are re-admitted to the hospital after being discharged post-surgery

  • Adverse EventsUp to 30 days post surgery

    Assessed by Clavien-Dindo Classification (grade 1-5, grade 1 being least severe and grade 5 being death)